Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Bullboard Posts
Comment by Sir_Holleron Jul 17, 2015 12:04pm
141 Views
Post# 23934435

RE:Going up on high volume

RE:Going up on high volume I thought the granting of 240,000 options to GUD recently had odd timing. It seemed like it may have been contingent upon achieving some event for I couldn't make sense of the timing otherwise. It also came shortly after the financing. I wonder if MPH has identified an second acquisition through GUD, after Apicore, to leverage its growing US salesforce. I'd love to see a transformative acquisition like we've seen with CRH which has seen the stock climb some five hundred percent. 

PI and Bloom Burton also underwrote the recent financing.
Maybe they've put out analyst reports. 
There was one analyst report listed on Yahoo! with a $3.50 target but that was before MPH blew away expectations last quarter with that surge in revenues.




Bullboard Posts